{"id":20285,"date":"2024-12-30T17:04:51","date_gmt":"2024-12-30T09:04:51","guid":{"rendered":"https:\/\/flcube.com\/?p=20285"},"modified":"2024-12-30T17:04:55","modified_gmt":"2024-12-30T09:04:55","slug":"wuxi-biologics-partners-with-sino-biopharmaceutical-for-first-in-class-monoclonal-antibody-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20285","title":{"rendered":"WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development"},"content":{"rendered":"\n<p>China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (<a href=\"https:\/\/www.google.com\/finance\/quote\/2269:HKG\">HKG: 2269<\/a>) has announced a significant research service cooperation agreement with fellow firm Sino Biopharmaceutical Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>). This partnership aims to empower Sino Biopharmaceutical in the development of a first-in-class monoclonal antibody (mAb), with the target currently undisclosed.<\/p>\n\n\n\n<p><strong>Comprehensive Research Services for Innovative mAb Development<\/strong><br>According to the agreement, WuXi Biologics will leverage its integrated research services and leading antibody discovery technology platforms, such as single-cell technology platforms, to generate antibodies based on targets specified by Sino Biopharmaceutical. This collaboration will encompass lead antibody discovery, optimization, and feasibility evaluation, with the goal of screening the best candidate mAbs from the preclinical development stage.<\/p>\n\n\n\n<p><strong>Sino Biopharmaceutical Takes the Lead in mAb Development and Commercialization<\/strong><br>Sino Biopharmaceutical will secure exclusive rights to the monoclonal antibody and will take the lead in subsequent Investigational New Drug (IND) filings, clinical trials, and product commercialization. This strategic move positions Sino Biopharmaceutical at the forefront of innovative drug development, bolstering its pipeline with a potentially groundbreaking therapy.<\/p>\n\n\n\n<p><strong>Financial Arrangements and Project Progress<\/strong><br>WuXi Biologics is set to receive corresponding payments that are contingent upon the project&#8217;s development and commercialization progress. This financial structure aligns incentives and ensures that both parties are committed to the successful advancement of the first-in-class monoclonal antibody from the research phase to market availability.<a href=\"https:\/\/flcube.com\/\">Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":20286,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[19,908,952,25,313,292],"class_list":["post-20285","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cro-cmo-cdmo","tag-hkg-1177","tag-hkg-2269","tag-potential-first-in-class","tag-sino-biopharmaceutical","tag-wuxi-biologics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a significant research service cooperation agreement with fellow firm Sino Biopharmaceutical Ltd (HKG: 1177). This partnership aims to empower Sino Biopharmaceutical in the development of a first-in-class monoclonal antibody (mAb), with the target currently undisclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20285\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development\" \/>\n<meta property=\"og:description\" content=\"China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a significant research service cooperation agreement with fellow firm Sino Biopharmaceutical Ltd (HKG: 1177). This partnership aims to empower Sino Biopharmaceutical in the development of a first-in-class monoclonal antibody (mAb), with the target currently undisclosed.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20285\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-30T09:04:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-30T09:04:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/3002.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"723\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20285#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20285\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development\",\"datePublished\":\"2024-12-30T09:04:51+00:00\",\"dateModified\":\"2024-12-30T09:04:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20285\"},\"wordCount\":237,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20285#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/3002.png\",\"keywords\":[\"CRO \\\/ CMO \\\/ CDMO\",\"HKG: 1177\",\"HKG: 2269\",\"Potential first-in-class\",\"Sino Biopharmaceutical\",\"WuXi Biologics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20285#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20285\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20285\",\"name\":\"WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20285#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20285#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/3002.png\",\"datePublished\":\"2024-12-30T09:04:51+00:00\",\"dateModified\":\"2024-12-30T09:04:55+00:00\",\"description\":\"China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a significant research service cooperation agreement with fellow firm Sino Biopharmaceutical Ltd (HKG: 1177). This partnership aims to empower Sino Biopharmaceutical in the development of a first-in-class monoclonal antibody (mAb), with the target currently undisclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20285#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20285\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20285#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/3002.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/3002.png\",\"width\":1080,\"height\":723,\"caption\":\"WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20285#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a significant research service cooperation agreement with fellow firm Sino Biopharmaceutical Ltd (HKG: 1177). This partnership aims to empower Sino Biopharmaceutical in the development of a first-in-class monoclonal antibody (mAb), with the target currently undisclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20285","og_locale":"en_US","og_type":"article","og_title":"WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development","og_description":"China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a significant research service cooperation agreement with fellow firm Sino Biopharmaceutical Ltd (HKG: 1177). This partnership aims to empower Sino Biopharmaceutical in the development of a first-in-class monoclonal antibody (mAb), with the target currently undisclosed.","og_url":"https:\/\/flcube.com\/?p=20285","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-30T09:04:51+00:00","article_modified_time":"2024-12-30T09:04:55+00:00","og_image":[{"width":1080,"height":723,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/3002.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20285#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20285"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development","datePublished":"2024-12-30T09:04:51+00:00","dateModified":"2024-12-30T09:04:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20285"},"wordCount":237,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=20285#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/3002.png","keywords":["CRO \/ CMO \/ CDMO","HKG: 1177","HKG: 2269","Potential first-in-class","Sino Biopharmaceutical","WuXi Biologics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20285#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20285","url":"https:\/\/flcube.com\/?p=20285","name":"WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=20285#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=20285#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/3002.png","datePublished":"2024-12-30T09:04:51+00:00","dateModified":"2024-12-30T09:04:55+00:00","description":"China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a significant research service cooperation agreement with fellow firm Sino Biopharmaceutical Ltd (HKG: 1177). This partnership aims to empower Sino Biopharmaceutical in the development of a first-in-class monoclonal antibody (mAb), with the target currently undisclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20285#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20285"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=20285#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/3002.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/3002.png","width":1080,"height":723,"caption":"WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20285#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/3002.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20285","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20285"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20285\/revisions"}],"predecessor-version":[{"id":20287,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20285\/revisions\/20287"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/20286"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20285"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20285"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20285"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}